GG747: Partner Glaxo Inc. started a Phase I U.S. trial

Amylin Pharmaceuticals Inc. (AMLN), San Diego Product: GG747 (AMLN's AC253) amylin blocker Indication: Type II (maturity onset) diabetes Status: Partner Glaxo Inc. started a Phase I U.S. trial to eval...